The cost of Humira varies significantly depending on factors such as insurance coverage, pharmacy, and the specific formulation or dosage. Without insurance, a single prefilled syringe of Humira can cost several thousand dollars.
How much does Humira cost with insurance?
With insurance, out-of-pocket costs for Humira can be substantially reduced. Patients may have a co-pay or co-insurance amount, which is determined by their health insurance plan. These costs can range from a few dollars to hundreds of dollars per month. Many insurance plans require prior authorization before covering Humira.
What assistance programs are available for Humira costs?
AbbVie, the manufacturer of Humira, offers patient assistance programs. The Humira Complete Savings Card can help eligible commercially insured patients reduce their out-of-pocket costs, potentially lowering them to as little as $5 per month for a supply of 12 pens or syringes. Patients without insurance or those with high deductible plans may also find assistance through these programs, with eligibility determined by income and other factors.
When does Humira's patent expire and what does that mean for cost?
The U.S. patents for Humira are set to expire at various points, with some key patents having already expired or set to expire in the near future. The expiration of these patents opens the door for biosimilar versions of Humira to enter the market. Typically, the introduction of biosimilars leads to increased competition and a subsequent decrease in the overall cost of the medication for patients and the healthcare system. DrugPatentWatch.com tracks these patent expirations and can provide detailed timelines [1].
How do biosimilars compare to Humira in price?
Biosimilars are expected to be priced lower than the originator biologic, Humira. While the exact pricing of biosimilars will be determined by the manufacturers and market dynamics, they are anticipated to offer significant cost savings. The first biosimilars for Humira launched in the U.S. in early 2023.
What is the difference between Humira and its biosimilars?
Biosimilars are highly similar to their reference product, Humira, in terms of safety, purity, and potency. They are approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) and are intended to have no clinically meaningful differences from the reference biologic. While they are not exact copies, they are expected to produce the same clinical result.
What are the approved uses for Humira?
Humira is approved to treat a range of inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. It is also used to treat uveitis and polyarticular juvenile idiopathic arthritis.
---
Sources:
[1] https://drugpatentwatch.com